Health Condition 1: - Health Condition 2: H598- Other intraoperative and postprocedural complications and disorders of eye and adnexa, not elsewhere classified
Conditions
Interventions
Intervention1: Subconjunctival injection of Bevacizumab: Subconjunctival injection of Bevacizumab 2.5 mg/0.1 ml ,3 doses at an interval of one month each .
Control Intervention1: NOT APPLICABLE: NOT A
Sponsors
SNMedical College
Eligibility
Inclusion criteria
Inclusion criteria: 1)patients having 2 or more than 2 quadrant corneal neovascularisation 2)patients who developed corneal neovascularisation during F/U ,not responding to conventional medical treatment . 3)patients who gave consent to be in follow up.
Exclusion criteria
Exclusion criteria: 1)patients having persistent epithelial defect 2)patients who were systemically not fit for subconj Bevacizumab injection;pts with H/O recent attack of M.I.,stroke and uncontrolled Hypertension. 3)pregnant female
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Corneal Neovascularization ParametersTimepoint: Follow up at an interval of one month after first dose of subconjunctival Bevacizumab till the completion of study period | — |
Secondary
| Measure | Time frame |
|---|---|
| Graft clarity,CCT and visual acuityTimepoint: Follow up at an interval of one month after first dose of subconjunctival Bevacizumab till the completion of study period | — |
Countries
India
Contacts
Public ContactDr Shefali Mazumdar
S.N.MedicalCollege Agra
Outcome results
None listed